HRTX Stock Analysis: Buy, Sell, or Hold?
HRTX - Heron Therapeutics, Inc.
$0.75
-0.04 (-4.82%)
▼
5d:
-6.72%
30d:
-37.32%
90d:
-41.73%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When HRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1.29
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$0.80
6.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRTX is currently trading at $0.75, which is considered oversold relative to its 30-day fair value range of $0.82 to $1.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.5) compared to its historical average (1.8). Remarkably, the market is currently pricing in an annual earnings decline of 7.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HRTX is in a strong downtrend. The price is currently testing key support at $0.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.33 (+480.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HRTX is in a strong downtrend. The price is currently testing key support at $0.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.33 (+480.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.82 -
$1.13
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 480.9% below Wall St target ($4.33)
- CAUTION: Recommendation downgraded due to -6.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$0.82 -
$1.13
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.75
Resistance Level
$0.93
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.46
Wall Street Target
$4.33
(+480.9%)
Revenue Growth (YoY)
-0.5%
Profit Margin
-13.0%
Valuation Discount vs History
-7.1% cheaper
PE vs Historical
1.5 vs 1.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.1%
(market-implied from PE analysis)
1-Year Target
$0.69
(-7%)
2-Year Target
$0.64
(-14%)
3-Year Target
$0.60
(-20%)
3-Yr Target (if PE normalizes)
(PE: 1→2)
$0.74
(-1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.5 to 1.8
Stabilization Target:
$0.92
(+23.1%)
PE Expansion Potential:
+23.1%
Share & Embed Analysis
Last updated: March 31, 2026 3:42 AM ET
Data refreshes hourly during market hours. Next update: 4:42 AM
Data refreshes hourly during market hours. Next update: 4:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
